Referral to and receipt of allogeneic hematopoietic stem cell transplantation in older adults with acute myeloid leukemia. Issue 1 (January 2023)

• Record Type: Journal Article
• Authors: Manogna, Dharmini; Lipof, Jodi J.; Baran, Andrea M.; Said, Bassil; Becker, Michael W.; Mendler, Jason H.; Aljitawi, Omar S.; O'Dwyer, Kristen M.; Huselton, Eric; Burack, Richard; Blaney, Margaret; Liesveld, Jane L.; Loh, Kah Poh
• Is Part Of: Journal of geriatric oncology. Volume 14:Issue 1(2023)
• Publication Date: 2023-01
• Subjects: Allogeneic hematopoietic stem cell transplantation -- Older adults -- Acute myeloid leukemia; Geriatric oncology -- Periodicals; Neoplasms -- Periodicals; Aged -- Periodicals; Geriatric oncology; Electronic journals; Periodicals; 618.976994005
• DOI: 10.1016/j.jgo.2022.11.002
• Languages: English
• ISSNs: 1879-4068

Abstract

Abstract: Introduction: Recent data have shown improved outcomes in selected older adults with acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation (HSCT). Nonetheless, practice patterns for referring and performing HSCT vary. We aimed to evaluate referral, utilization, and reasons for not referring/proceeding to HSCT in older adults with AML. Materials and Methods: This is a single center retrospective analysis of patients aged ≥60 years diagnosed with AML evaluating rates of HSCT referral and utilization. Fisher's exact test was used to compare rates of referral and utilization across age groups and years of diagnosis. Results: Median age of the 97 patients was 70 years (range 61–95); 30% (29/97) were referred for HSCT and of these, 69% (20/29) received HSCT. Common documented reasons (can be multiple) for not referring were performance status ( n = 21), advanced age ( n = 16), patient refusal ( n = 15), refractory disease ( n = 14), and prohibitive comorbidity ( n = 6). Among patients who were referred but did not receive HSCT ( n = 9/29), documented reasons for not proceeding with HSCT were refractory disease ( n = 5), advanced age (n = 2), and prohibitive comorbidity (n = 2). HSCT referral and utilization rates significantly decreased with age ( p < 0.01) but were generally stable over time from 2014 to 2017 ( p = 0.40 for referral and p = 0.56 for utilization). Discussion: Despite improvements in supportive care and HSCT techniques, HSCT referral and utilization rates remained low among older adults with AML but stable over time.